1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Cardiovascular Surgery Devices Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 7
3 Cardiovascular Surgery Devices Market, United States 9
3.1 Cardiovascular Surgery Devices Market, United States, Revenue ($m), 2015-2025 9
3.1.1 Beating Heart Surgery Systems Market, United States, Revenue ($m), by Segment, 2015-2025 11
3.1.2 Perfusion Disposables Market, United States, Revenue ($m), by Segment, 2015-2025 13
3.2 Cardiovascular Surgery Devices Market, United States, Volume (Units), 2015-2025 15
3.2.1 Beating Heart Surgery Systems Market, United States, Volume (Units), by Segment, 2015-2025 17
3.2.2 Perfusion Disposables Market, United States, Volume (Units), by Segment, 2015-2025 19
3.3 Cardiovascular Surgery Devices Market, United States, Average Price ($), 2015-2025 21
3.4 Cardiovascular Surgery Devices Market, United States, Distribution Share by Revenue ($m), 2019 23
3.5 Cardiovascular Surgery Devices Market, United States, Company Share by Revenue ($m), 2019 24
4 Overview of Key Companies in United States, Cardiovascular Surgery Devices Market 26
4.1 Medtronic Plc 26
4.1.1 Company Overview 26
4.2 Terumo Medical Corp 26
4.2.1 Company Overview 26
4.3 LivaNova PLC 26
4.3.1 Company Overview 26
4.4 Maquet Holding BV & Co KG 27
4.4.1 Company Overview 27
5 Cardiovascular Surgery Devices Market Pipeline Products 28
6 Financial Deals Landscape 30
6.1 Acquisition 30
6.1.1 AtriCure to Acquire SentreHEART 30
6.2 Debt Offerings 32
6.2.1 CryoLife Prices Private Placement of
4.250% Notes Due 2025 for USD100 Million 32
6.2.2 Boston Scientific Raises USD1.2 Billion in Public Offering of
2.65% Senior Notes due 2030 34
6.2.3 Boston Scientific Raises USD500 Million in Public Offering of
1.9% Senior Notes due 2025 36
6.2.4 Integra LifeSciences Prices Private Placement of
0.5% Convertible Senior Notes Due 2025 for USD500 Million 38
6.2.5 Boston Scientific Raises USD999.2 Million in Public Offering of
0.625% Notes Due 2027 40
6.3 Equity Offerings 42
6.3.1 SurModics Plans to Raise up to USD200 Millon in Public Offering of Securities 42
6.3.2 Boston Scientific Raises USD1 Billion in Public Offering of Shares 43
6.3.3 Boston Scientific Raises USD1 Billion in Public Offering of
5.5% Mandatory Convertible Preferred Stock 45
6.3.4 Lemaitre Vascular Files Registration Statement for Public Offering of Securities for up to USD200 Million 47
6.3.5 SI-Bone Prices USD92.45 Million Public Offeirng of Shares 48
6.3.6 SI-Bone Plans to Raise up to USD200 Million in Public Offering of Securities 50
6.4 Venture Financing 51
6.4.1 NuPulseCV Raises USD2.1 Million in Venture Financing 51
6.4.2 Emboline Raises USD5 Million in Financing 52
6.4.3 Scinovia Raises Additional USD1 Million in Venture Financing 53
7 Recent Developments 54
7.1 Corporate Communications 54
7.1.1 Feb 03, 2020: Surmodics names Nusrath Sultana, MD, as Vice President, Clinical Affairs 54
7.1.2 Jan 31, 2020: Emboline completes $5m bridge round of financing 54
7.1.3 Dec 16, 2019: MiMedx Announces addition of Peter M. Carlson 55
7.1.4 Dec 06, 2019: Gilero opens new design center in Southern California 55
7.1.5 Dec 04, 2019: SI-BONE names Jeryl Hilleman to Board of Directors 56
7.1.6 Nov 26, 2019: MiMedx names William "Butch" Hulse as General Counsel and Secretary 56
7.1.7 Sep 20, 2019: MiMedx announces resignation of board member 57
7.1.8 Aug 19, 2019: Merit Medical announces appointment of Lynne N. Ward to its Board of Directors 57
7.1.9 Aug 13, 2019: SI-BONE: Departure of directors or certain officers 57
7.1.10 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 58
7.2 Financial Announcements 58
7.2.1 Feb 24, 2020: Merit Medical reports earnings for fourth quarter and year ended December 31, 2019, gives FY 2020 Guidance 58
7.2.2 Feb 19, 2020: Integra LifeSciences reports fourth quarter and full-year 2019 financial results and provides 2020 financial guidance 60
7.2.3 Feb 13, 2020: CryoLife reports fourth quarter and full year 2019 financial results 61
7.2.4 Feb 06, 2020: LeMaitre Vascular Announces Q4 2019 Financial Results 62
7.2.5 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019 62
7.2.6 Feb 05, 2020: Surmodics reports first quarter Fiscal 2020 results 64
7.2.7 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019 65
7.2.8 Jan 09, 2020: SI-BONE reports preliminary unaudited revenue for fourth quarter and full year 2019 and provides full year 2020 revenue guidance 66
7.2.9 Nov 11, 2019: SI-BONE reports third quarter 2019 financial results and updates full-year 2019 revenue guidance 67
7.2.10 Oct 31, 2019: Surmodics reports fourth quarter fiscal 2019 results and issues fiscal 2020 revenue and EPS Guidance 68
7.2.11 Oct 30, 2019: CryoLife reports third quarter 2019 financial results 68
7.2.12 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019 69
7.2.13 Oct 24, 2019: Integra LifeSciences reports third quarter 2019 financial results 72
7.2.14 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 73
7.2.15 Oct 23, 2019: Edwards Lifesciences reports third quarter results 75
7.2.16 Oct 23, 2019: LeMaitre Vascular announces Q3 2019 financial results 77
7.2.17 Aug 06, 2019: SI-BONE reports second quarter 2019 financial results 77
7.2.18 Jul 31, 2019: Surmodics reports third quarter fiscal 2019 results and raises fiscal 2019 revenue and EPS guidance 78
7.2.19 Jul 30, 2019: CryoLife reports second quarter 2019 financial results 79
7.2.20 Jul 25, 2019: Merit Medical reports earnings for second quarter of 2019 80
7.2.21 Jul 24, 2019: Integra LifeSciences reports second quarter 2019 financial results 82
7.2.22 Jul 24, 2019: LeMaitre Vascular announces Q2 2019 financial results 83
7.2.23 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 83
7.2.24 Jul 23, 2019: Edwards Lifesciences reports second quarter results for the year 2019 85
7.3 Government and Public Interest 87
7.3.1 Jan 27, 2020: Merit Medical issues statement regarding director nominations from starboard 87
7.3.2 Aug 01, 2019: FRESH 3D printing used to rebuild functional components of human heart 87
7.4 Legal And Regulatory 88
7.4.1 Apr 06, 2020: MiMedx Group agrees to pay $6.5 million to resolve false claims act allegations of false commercial pricing disclosures 88
7.4.2 Nov 26, 2019: MiMedx announces Securities and Exchange Commission Settlement 89
7.4.3 Nov 26, 2019: SEC charges biotech company and executives with accounting fraud 89
7.4.4 Sep 30, 2019: Mallinckrodt finalizes settlement to resolve "Track 1" opioid cases with the Ohio Counties of Cuyahoga and Summit 90
7.4.5 Sep 06, 2019: Mallinckrodt announces settlement in principle to resolve "Track 1" opioid cases with the Ohio Counties of Cuyahoga and Summit 91
7.4.6 Sep 04, 2019: Faruqi & Faruqi Encourages Investors who suffered losses exceeding $50,000 in Mallinckrodt to contact the Firm 91
7.4.7 Sep 03, 2019: Mallinckrodt announces completion of previously disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor sales and marketing activities 92
7.5 Other Significant Developments 92
7.5.1 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific 92
7.5.2 Apr 02, 2020: SI-BONE provides business update in response to covid-19 pandemic 93
7.5.3 Feb 28, 2020: Long Beach Medical Center only Southern California site participating in AFib clinical trial 93
7.5.4 Nov 04, 2019: Ernie Green Industries and Gilero announce business realignment 94
7.5.5 Oct 10, 2019: CINDE announces Edwards Lifesciences invests $100 million to expand its operations in Costa Rica 95
7.5.6 Sep 11, 2019: CryoLife enters into distribution agreement with Endospan 96
7.5.7 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 97
7.5.8 Aug 01, 2019: NIH Grant for Cardiothoracic Surgery Awarded 98
7.5.9 Jul 10, 2019: Medtronic announces the early results of its cash tender offers for up to $5.525 billion of certain outstanding debt securities 99
7.6 Strategy And Business Planning 100
7.6.1 Feb 11, 2020: Celerion expands clinical research to Nebraska Innovation Campus 100
7.6.2 Jan 15, 2020: Merit milestones: facilities in Galway and Tijuana reach 1,000 employees 100
7.6.3 Dec 06, 2019: Gilero opens new design center in Southern California 101
8 Appendix 102
8.1 Research Methodology 103
8.1.1 Coverage 103
8.1.2 Secondary Research 103
8.1.3 Primary Research 104
8.1.4 Market Modeling and Forecasting 105
8.1.5 Company Share Analysis 107
8.1.6 Distribution Share Analysis 107
8.1.7 Benchmarking 107
8.2 GlobalData Consulting 108
8.3 Contact Us 108
8.4 Disclaimer 109
